CORINNE MARSOLIER

Corinne Marsolier stands as a pivotal investor within Angels Sante, a distinguished network committed to fostering groundbreaking innovation across the healthcare spectrum. As an active member, Corinne plays a crucial role in identifying, evaluating, and nurturing early-stage companies that promise to reshape the future of health and wellness. Her dedication to supporting visionary entrepreneurs is central to Angels Sante's mission of bringing transformative health solutions to market.

Corinne's investment focus is broad yet strategic, primarily targeting sectors ripe for disruption and significant societal impact. She is particularly keen on digital health platforms that enhance patient care and accessibility, biotechnology firms developing novel therapies, and medical technology innovations that improve diagnostics and treatment outcomes. Her portfolio also extends to preventative care solutions, personalized medicine initiatives, and companies leveraging artificial intelligence to solve complex health challenges. Corinne seeks out ventures with robust scientific foundations, scalable business models, and, most importantly, passionate and capable founding teams.

Before dedicating her expertise to angel investing, Corinne Marsolier built a formidable career grounded in both scientific rigor and strategic business development. Holding a Master's degree in Biomedical Sciences, she initially spent several years in research and development at a leading pharmaceutical corporation, gaining invaluable insights into drug discovery and clinical trials. This foundational experience was complemented by a subsequent role in business development for a health tech startup, where she honed her skills in market analysis, partnership building, and scaling innovative solutions. This unique blend of scientific understanding and commercial acumen positions her as a highly effective and empathetic investor.

Among her notable contributions, Corinne has been an early supporter of several promising ventures. She invested in 'MediSense AI,' a pioneering platform utilizing artificial intelligence for early disease detection, which has since gained significant traction in diagnostic imaging. Another key investment includes 'BioGen Therapeutics,' a biotech firm focused on developing advanced gene therapies for rare diseases, demonstrating her commitment to high-impact scientific breakthroughs. Her involvement often extends beyond capital, providing strategic guidance and leveraging her extensive network to help portfolio companies achieve their milestones and accelerate their growth. Corinne Marsolier's work at Angels Sante continues to drive innovation, making a tangible difference in the global health landscape.